Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.01 USD | +2.35% | -1.96% | -4.94% |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.94% | 1.03B | - | ||
-2.31% | 103B | B+ | ||
+0.56% | 95.28B | B+ | ||
+1.69% | 22.15B | B | ||
-17.37% | 21.02B | B+ | ||
-9.30% | 18.15B | A- | ||
-41.01% | 16.74B | A- | ||
-14.85% | 16.05B | B | ||
+3.21% | 13.68B | C+ | ||
+33.54% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- IMTX Stock
- Ratings Immatics N.V.